X @Bloomberg
Bloomberg·2026-07-30 01:15
Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US IPO https://t.co/KuPFpbYaDN ...
Attovia, an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US IPO https://t.co/KuPFpbYaDN ...